Biotech Amarin (NASDAQ:AMRN) has slide more than 20% since launching its hypertriglyceridemia drug Vascepa in January. The company's market value has dropped following months of indecision regarding the drug's exclusivity status and question marks over the drug's launch. As the stock continues to be hotly debated, there are two catalysts in particular that investors should watch. Health-care analyst Max Macaluso discusses each in the following video.

Editor's Note: At 1:00, the speaker meant to say eight months.

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.